Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immune Modulation by Abemaciclib in HPV-Negative Head and Neck Squamous Cell Carcinoma (HNSCC): A Phase II Window Trial.

NCT04169074 is registered in ClinicalTrials.gov with University of Arizona as lead sponsor.

NCT NCT04169074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04169074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immune Modulation by Abemaciclib in HPV-Negative Head and Neck Squamous Cell Carcinoma (HNSCC): A Phase II Window Trial.
Lead sponsor
University of Arizona
Phase
Phase 2
Overall status
Terminated
Start date
July 7, 2021
Completion date
January 13, 2025
Enrollment
7 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hnscc